Triple

T1143373
Position Surface form Disambiguated ID Type / Status
Subject European Centre for Disease Prevention and Control E23505 entity
Predicate focusesOn P31 FINISHED
Object COVID-19 E67147 NE FINISHED

How this triple was built (2 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: COVID-19 | Statement: [European Centre for Disease Prevention and Control, focusesOn, COVID-19]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07
Target entity: COVID-19
Context triple: [European Centre for Disease Prevention and Control, focusesOn, COVID-19]
  • A. COVID-19 pandemic chosen
    The COVID-19 pandemic is a global outbreak of the coronavirus SARS-CoV-2 that began in late 2019, causing widespread illness, deaths, and major disruptions to societies and economies worldwide.
  • B. Omicron
    Omicron is a vowel letter of the Greek alphabet, historically representing a short "o" sound and used today in various scientific and mathematical contexts.
  • C. COVID-19 vaccines
    COVID-19 vaccines are immunizations developed to protect against the SARS-CoV-2 virus, significantly reducing the risk of severe illness, hospitalization, and death from COVID-19.
  • D. Janssen COVID-19 Vaccine
    The Janssen COVID-19 Vaccine is a single-dose, viral vector-based coronavirus vaccine developed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, for the prevention of COVID-19.
  • E. Leqembi
    Leqembi is an Alzheimer’s disease drug (lecanemab) that targets amyloid-beta plaques to slow cognitive decline in early-stage patients.
  • F. None of above.
  • G. Unsure - the case is ambiguous/there is not enough information to decide.

Provenance (3 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69a493ef399c8190b04b9146d2314f59 completed March 1, 2026, 7:30 p.m.
NER Named-entity recognition batch_69a4bc4e93d48190b9fea886bf61aad7 completed March 1, 2026, 10:23 p.m.
NED1 Entity disambiguation (via context triple) batch_69ac59b2395c81909d4608bdaf1d57e8 completed March 7, 2026, 5 p.m.
Created at: March 1, 2026, 7:44 p.m.